ホーム>>Signaling Pathways>> Chromatin/Epigenetics>> Histone Demethylases>>KDM2A/7A-IN-1

KDM2A/7A-IN-1

カタログ番号GC36388

KDM2A/7A-IN-1 は、ヒストン リジン デメチラーゼ KDM2A/7A のクラス初の選択的細胞透過性阻害剤であり、KDM2A の IC50 は 0.16 μM であり、他の JmjC リジン デメチラーゼよりも 75 倍の選択性を示します。メチルトランスフェラーゼおよびヒストンアセチルトランスフェラーゼに対して不活性です。

Products are for research use only. Not for human use. We do not sell to patients.

KDM2A/7A-IN-1 化学構造

Cas No.: 2169272-46-0

サイズ 価格 在庫数 個数
100mg Please Inquire Please Inquire
250mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

KDM2A/7A-IN-1 is a first-in-class, selective and cell-permeable inhibitor of histone lysine demethylases KDM2A/7A, with an IC50 of 0.16 μM for KDM2A, exhibits 75 fold selevtivity over other JmjC lysine demethylases, and is inactive on methyl transferases, and histone acetyl transferases[1]. IC50: 0.16 μM (KDM2A)[1]

KDM2A/7A-IN-1 ((S,S)-6) is a first-in-class, selective and cell-permeable inhibitor of histone lysine demethylases KDM2A/7A, with an IC50 of 0.16 μM for KDM2A, exhibits 75 fold selevtivity over other JmjC lysine demethylases, and is inactive to methyl transferases, and histone acetyl transferases[1].KDM2A/7A-IN-1 (0.4, 3.1, 6.2 μM) augments cellular H3K36me2 levels in HeLa cells ectopically expressing catalytically active KDM2A[1].

[1]. Gerken PA, et al. Discovery of a Highly Selective Cell-Active Inhibitor of the Histone Lysine Demethylases KDM2/7. Angew Chem Int Ed Engl. 2017 Dec 4;56(49):15555-15559.

レビュー

Review for KDM2A/7A-IN-1

Average Rating: 5 ★★★★★ (Based on Reviews and 29 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for KDM2A/7A-IN-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.